ALSU联合#64：丁酸盐

IF 2.5 4区医学 Q2 CLINICAL NEUROLOGY

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Pub Date : 2022-02-28 DOI:10.1080/21678421.2022.2045323

Yuyao Sun, R. Bedlack, C. Armon, Morgan Beauchamp, T. Bertorini, R. Bowser, M. Bromberg, J. Caress, Gregory T. Carter, J. Crayle, M. Cudkowicz, J. Glass, Carlayne Jackson, Isaac Lund, Sarah Martin, S. Paganoni, G. Pattee, Dylan Ratner, Kristiana Salmon, Paul Wicks

{"title":"ALSU联合#64：丁酸盐","authors":"Yuyao Sun, R. Bedlack, C. Armon, Morgan Beauchamp, T. Bertorini, R. Bowser, M. Bromberg, J. Caress, Gregory T. Carter, J. Crayle, M. Cudkowicz, J. Glass, Carlayne Jackson, Isaac Lund, Sarah Martin, S. Paganoni, G. Pattee, Dylan Ratner, Kristiana Salmon, Paul Wicks","doi":"10.1080/21678421.2022.2045323","DOIUrl":null,"url":null,"abstract":"Abstract ALSUntangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here we review butyrate and its different chemical forms (butyrates). Butyrates have plausible mechanisms for slowing ALS progression and positive pre-clinical studies. One trial suggests that sodium phenylbutyrate (NaPB) in combination with Tauroursodeoxycholic acid (TUDCA) can slow ALS progression and prolong survival, but the specific contribution of NaPB toward this effect is unclear. Butyrates appear reasonably safe for use in humans. Based on the above information, we support a trial of a butyrate in PALS, but we cannot yet recommend one as a treatment.","PeriodicalId":7740,"journal":{"name":"Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration","volume":"23 1","pages":"638 - 643"},"PeriodicalIF":2.5000,"publicationDate":"2022-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":"{\"title\":\"ALSUntangled #64: butyrates\",\"authors\":\"Yuyao Sun, R. Bedlack, C. Armon, Morgan Beauchamp, T. Bertorini, R. Bowser, M. Bromberg, J. Caress, Gregory T. Carter, J. Crayle, M. Cudkowicz, J. Glass, Carlayne Jackson, Isaac Lund, Sarah Martin, S. Paganoni, G. Pattee, Dylan Ratner, Kristiana Salmon, Paul Wicks\",\"doi\":\"10.1080/21678421.2022.2045323\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract ALSUntangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here we review butyrate and its different chemical forms (butyrates). Butyrates have plausible mechanisms for slowing ALS progression and positive pre-clinical studies. One trial suggests that sodium phenylbutyrate (NaPB) in combination with Tauroursodeoxycholic acid (TUDCA) can slow ALS progression and prolong survival, but the specific contribution of NaPB toward this effect is unclear. Butyrates appear reasonably safe for use in humans. Based on the above information, we support a trial of a butyrate in PALS, but we cannot yet recommend one as a treatment.\",\"PeriodicalId\":7740,\"journal\":{\"name\":\"Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration\",\"volume\":\"23 1\",\"pages\":\"638 - 643\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2022-02-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/21678421.2022.2045323\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/21678421.2022.2045323","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 5

摘要

摘要ALS综述了肌萎缩侧索硬化症（PALS）患者的替代和非标签治疗方法。本文综述了丁酸盐及其不同的化学形式（丁酸盐）。丁酸盐具有减缓ALS进展的合理机制和积极的临床前研究。一项试验表明，苯丁酸钠（NaPB）与牛磺酸脱氧胆酸（TUDCA）联合使用可以减缓ALS的进展并延长生存期，但NaPB对这种作用的具体作用尚不清楚。丁酸盐在人体中使用似乎相当安全。基于上述信息，我们支持丁酸盐治疗PALS的试验，但我们还不能推荐一种治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

ALSUntangled #64: butyrates

Abstract ALSUntangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here we review butyrate and its different chemical forms (butyrates). Butyrates have plausible mechanisms for slowing ALS progression and positive pre-clinical studies. One trial suggests that sodium phenylbutyrate (NaPB) in combination with Tauroursodeoxycholic acid (TUDCA) can slow ALS progression and prolong survival, but the specific contribution of NaPB toward this effect is unclear. Butyrates appear reasonably safe for use in humans. Based on the above information, we support a trial of a butyrate in PALS, but we cannot yet recommend one as a treatment.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration CLINICAL NEUROLOGY-

CiteScore

5.40

自引率

10.70%

发文量

期刊介绍： Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration is an exciting new initiative. It represents a timely expansion of the journal Amyotrophic Lateral Sclerosis in response to the clinical, imaging pathological and genetic overlap between ALS and frontotemporal dementia. The expanded journal provides outstanding coverage of research in a wide range of issues related to motor neuron diseases, especially ALS (Lou Gehrig’s disease) and cognitive decline associated with frontotemporal degeneration. The journal also covers related disorders of the neuroaxis when relevant to these core conditions.